Literature DB >> 17089108

The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.

Tore Haslemo1, Per Haakon Eikeseth, Lars Tanum, Espen Molden, Helge Refsum.   

Abstract

OBJECTIVE: Cigarette smoking has been shown in several studies to induce the metabolism of the cytochrome P4501A2 (CYP1A2) substrates clozapine and olanzapine. The aim of the present study was to investigate the dose-dependent effect of cigarette smoking on serum concentrations of these drugs in a naturalistic setting.
METHODS: In 73 schizophrenic patients recruited from psychiatric nursing homes, patient characteristics, smoking habits, drug dosing and serum concentrations of clozapine (n=33) and olanzapine (n=40) were registered. Concentration to dose (C/D) ratios of clozapine and olanzapine in non-smokers and subgroups of smokers were compared.
RESULTS: Fifty-nine patients (80%) were smokers and these were stratified into the following groups according to smoking habits: 1-6 (n=0), 7-12 (n=13), 13-19 (n=18) and >or=20 (n=28) cigarettes daily. While the mean ratio was twice as high in non-smokers compared to smokers for both drugs (p<0.01), the C/D ratios of clozapine and olanzapine were not significantly different between the subgroups of smokers (p >0.15). Absolute serum concentrations were also higher in non-smokers compared to smokers: 50% for clozapine (p=0.058) and 67% for olanzapine (p<0.01).
CONCLUSION: A daily consumption of 7-12 cigarettes is probably sufficient for maximum induction of clozapine and olanzapine metabolism. A 50% lower starting dose of both drugs in non-smokers seems rational to avoid side effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089108     DOI: 10.1007/s00228-006-0209-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline.

Authors:  P Baumann; C Hiemke; S Ulrich; I Gaertner; M L Rao; G Eckermann; M Gerlach; H J Kuss; G Laux; B Müller-Oerlinghausen; P Riederer; G Zernig
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

Review 2.  Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring.

Authors:  Ahsan Y Khan; Sheldon H Preskorn
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

3.  Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.

Authors:  Guido Bondolfi; Françoise Morel; Séverine Crettol; Fady Rachid; Pierre Baumann; Chin B Eap
Journal:  Ther Drug Monit       Date:  2005-08       Impact factor: 3.681

4.  Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.

Authors:  D F Zullino; D Delessert; C B Eap; M Preisig; P Baumann
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  The association of weight gain and olanzapine plasma concentrations.

Authors:  Paul J Perry; Tami R Argo; Ryan M Carnahan; Brian C Lund; Timothy L Holman; Vicki L Ellingrod; Del Miller
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

7.  The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.

Authors:  Jan van der Weide; Linda S Steijns; Marga J van Weelden
Journal:  Pharmacogenetics       Date:  2003-03

8.  Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients.

Authors:  Kari Raaska; Virpi Raitasuo; Jouko Laitila; Pertti J Neuvonen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2004-01       Impact factor: 4.080

9.  Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?

Authors:  Philip J Tyson; Kate H Roberts; Ann M Mortimer
Journal:  Int J Neurosci       Date:  2004-06       Impact factor: 2.292

10.  Sex differences in the risk of schizophrenia: evidence from meta-analysis.

Authors:  Andre Aleman; René S Kahn; Jean-Paul Selten
Journal:  Arch Gen Psychiatry       Date:  2003-06
View more
  34 in total

1.  Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Authors:  David R Plowchalk; Karen Rowland Yeo
Journal:  Eur J Clin Pharmacol       Date:  2012-01-19       Impact factor: 2.953

Review 2.  The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations.

Authors:  Jaimee L Heffner; Jeffrey R Strawn; Melissa P DelBello; Stephen M Strakowski; Robert M Anthenelli
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

Review 3.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 4.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 5.  Smoking in schizophrenic patients: A critique of the self-medication hypothesis.

Authors:  Francesca Manzella; Susan E Maloney; George T Taylor
Journal:  World J Psychiatry       Date:  2015-03-22

6.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

7.  Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

Authors:  Karolina Kozak; Tony P George
Journal:  Expert Opin Pharmacother       Date:  2020-02-03       Impact factor: 3.889

8.  Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.

Authors:  Christina P C Borba; Xiaoduo Fan; Paul M Copeland; Alexander Paiva; Oliver Freudenreich; David C Henderson
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

Review 9.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

10.  Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels.

Authors:  Eunkyoung Kim; Yi Liu; Hadar Ben-Yoav; Thomas E Winkler; Kun Yan; Xiaowen Shi; Jana Shen; Deanna L Kelly; Reza Ghodssi; William E Bentley; Gregory F Payne
Journal:  Adv Healthc Mater       Date:  2016-09-12       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.